Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 56,129 | 40,265 | 48,616 | 31,194 | 48,887 |
| Receivables | 44 | 25,387 | 2,459 | 26,913 | 24,279 |
| TOTAL | $57,612 | $67,286 | $52,323 | $59,402 | $74,714 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 1,409 | 1,633 | 1,847 | 2,717 | 2,995 |
| TOTAL | $1,409 | $1,633 | $1,847 | $2,717 | $2,995 |
| Total Assets | $59,021 | $68,919 | $54,170 | $62,119 | $77,709 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 217 | 693 | 1,395 | 780 | 1,765 |
| Accrued Expenses | 3,142 | 5,578 | 7,809 | 6,727 | 8,188 |
| TOTAL | $5,489 | $8,868 | $13,649 | $14,945 | $29,155 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 258 | 2,383 | 5,431 | 17,233 |
| Other Non-Current Liabilities | 598 | 1,030 | 1,452 | 1,771 | 2,165 |
| TOTAL | $598 | $1,030 | $14,027 | $14,346 | $14,740 |
| Total Liabilities | $6,087 | $9,898 | $27,676 | $29,291 | $43,895 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 57,901 | 57,891 | 56,339 | 56,275 | 55,911 |
| Common Shares | 58 | 56 | 56 | 56 | 56 |
| Retained earnings | -458,269 | -451,066 | -482,586 | -475,204 | -473,504 |
| TOTAL | $52,934 | $59,021 | $26,494 | $32,828 | $33,814 |
| Total Liabilities And Equity | $59,021 | $68,919 | $54,170 | $62,119 | $77,709 |